Life Sciences
Top stories summarized by our editors
2/21/2019

Swiss biotech BioLingus and WuXi AppTec's subsidiary STA Pharmaceutical, a contract development and manufacturing organization, agreed to collaborate on sublingual delivery of drugs in a deal that allows BioLingus' sublingual and buccal delivery technology to be exclusively accessed by WuXi STA.

Full Story:
FierceBiotech
2/21/2019

Italy-based scientists have begun large-scale testing of biotech mosquitoes in a controlled laboratory that mimics their natural environment. The biotech mosquitoes have the doublesex gene mutation, resulting in malformed reproductive organs that prevent female mosquitoes from laying eggs and mouths more like those of male mosquitoes that are incapable of biting or spreading diseases.

Full Story:
The Scientist online
2/21/2019

An independent data safety monitory board looked at a post-marketing study of Pfizer's rheumatoid arthritis treatment Xeljanz and observed that patients on a twice-daily, 10 mg dose had higher rates of pulmonary embolism and death than a comparison group taking a 5 mg dose twice a day. Pfizer says it is taking steps to transition patients taking the 10 mg dose to a 5 mg dose.

Full Story:
FiercePharma
More Summaries:
Pfizer, pulmonary embolism, Xeljanz
2/21/2019

Medtronic has announced a cash tender offer of senior notes amounting to up to $5 billion in outstanding debt. The company's offer includes $2.5 billion in 2.5% senior notes and $600 million in 4.2% senior notes, all due in 2020.

Full Story:
MassDevice (Boston)
More Summaries:
Medtronic
2/21/2019

Medtronic is introducing its deep brain stimulation therapy for epilepsy in the US. The system uses an implanted device that releases electrical pulses to the anterior nucleus of the thalamus to reduce partial-onset seizures in patients with resistance to at least three anti-epilepsy medications.

Full Story:
FierceBiotech
More Summaries:
Medtronic
2/21/2019

Novo Nordisk has added the Freestyle Libre continuous glucose monitoring system by Abbott to the list of data platforms to be integrated into its new line of connected insulin pens. The Freestyle Libre system will link the pens with the FreeStyle LibreLink mobile app and the LibreView cloud-based system.

Full Story:
MobiHealthNews
More Summaries:
Novo Nordisk, Abbott
2/21/2019

Data from a study that evaluated Apollo Endosurgery's OverStitch endoscopic suturing system for endoscopic gastroplasty showed remission of all cases of hypertension and 13 of 17 cases of type 2 diabetes in patients three months after surgery. No mortalities were recorded, and none of the patients required an emergency intervention.

More Summaries:
Apollo
2/21/2019

A study in ACS Nano indicates the beating of the heart can be converted into energy through piezoelectric layers attached to a flexible frame, and this energy can then be harnessed to power a pacemaker. This type of heart-powered pacemaker would address a problem seen in other experimental pacemakers, where the rigid structure limits the device's power.

Full Story:
HealthDay News
2/21/2019

SyncThink's EYE-SYNC device for evaluating patients with possible concussion has been awarded breakthrough designation by the FDA. The device is one of a number of concussion-related technologies that the FDA has reviewed in recent months.

Full Story:
MedTech Dive
More Summaries:
FDA, SyncThink
2/21/2019

A CE mark was granted to Abbott's Determine HBsAg 2 immunoassay for use in detecting hepatitis B surface antigen. Abbott said its test has an analytical sensitivity of 0.1 IU/mL and determines HBV status within 15 minutes.

More Summaries:
Abbott